AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03146871 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT03146871 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant EphB4-HSA Fusion Protein
Description: Given IV
Study NCT04666844 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: Observational Study
Study NCT01920256 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Remote, personalized type 2 diabetes care.
Description: Diabetes and comorbidities will be managed with 1 clinic visit per year and frequent adjustments made remotely.
Study NCT01920256 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Endocrine care.
Description: Diabetes and comorbidities management will provided by an endocrinologist
Study NCT01859962 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PPI-668
Study NCT01859962 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BI 207127 Dose 1
Study NCT01859962 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BI 207127 Dose 2
Study NCT01859962 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Faldaprevir
Study NCT01859962 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Study NCT01859962 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BI 207127 Placebo
Study NCT02258269 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: SQ
Study NCT02258269 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SQ
Study NCT02258269 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control
Study NCT02258269 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Study NCT04414189 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: HostDx Sepsis
Description: Blood collection for mRNA analysis
Study NCT00865267 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ultravate® 0.05% ointment, single exposure
Description: A: Experimental Subjects received Bristol-Myers Squibb Company formulated products
Study NCT01254721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine fumarate
Description: eXtended Release(XR) 50mg, 200mg, 300mg and/or 400mg tablet, oral, once daily in the evening, from assignment to the end of the study.
Study NCT01254721 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quetiapine fumarate
Description: eXtended Release(XR) 50mg, 200mg, 300mg and/or 400mg tablet, oral, once daily in the evening, from assignment to the end of the study.
Study NCT01254721 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lithium
Description: 300mg tablet, oral
Study NCT04438499 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: eSense 7fr Single Sensor Bladder Catheter
Description: Urinary and abdominal catheters inserted in to the body to measure pressure for urodynamics.
Study NCT00746317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GC33
Description: IV administration at 4 escalating dose levels.
Study NCT03319186 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EDIT Management
Description: EDIT management~1. Volumetric Pleural MRI for pre-aspiration pleural cavity volume~2. Large volume pleural aspiration with recording of intra-pleural pressure during aspiration~3. Volumetric Pleural MRI for post-aspiration pleural cavity volume~4. Computation of PEL250, defined as the rolling average of pleural elastance over the preceding 250ml aspirated.~   MaxPEL250 ≥ 14.5 cm H2O/L: allocated to 1st-line IPC MaxPEL250 \< 14.5 cm H2O/L: allocated to 1st-line TP~5. EDIT-directed 1st-line treatment to be delivered within 24 hours; if insufficient residual pleural fluid to allow standard Seldinger insertion technique then Boutin-type needle used for pneumothorax induction and guide wire insertion.
Study NCT03319186 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Chest drain and talc pleurodesis
Description: Intercostal chest drain insertion and talc slurry instillation according to British Thoracic Society guidelines
Study NCT03918538 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home rehabilitation exercise program
Description: After pre-test, the intervention participants received a 60 minutes of teaching regarding the home rehabilitation exercise program, with a printed exercise manual. The intervention participants also received a weekly phone call from the interventionist to enhance their exercise adherence and helping to overcome exercise barriers.
Study NCT02442856 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thigh Cuff
Study NCT02134522 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure (CPAP).
Description: Continuous positive airway pressure is a commonly prescribed therapy for obstructive sleep apnea which is recommended for the treatment of obstructive sleep apnea in children and adults.
Study NCT01361126 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Coagulation Factor IX Albumin Fusion Protein
Description: Study subjects will receive a single dose of 25IU/kg of rIX_FP for pharmacokinetic analysis. Subjects will then be treated for approximately 5 months. The treatment dose will be based on the subject's PK profile and the subject's bleeding phenotype.
Study NCT01930461 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SLIT tablets of HDM allergen extracts, 3 different doses (A)
Description: Two sublingual tablets daily for 13 months
Study NCT01930461 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SLIT tablets of HDM allergen extracts, 3 different doses (B)
Description: Two sublingual tablets daily for 13 months
Study NCT01930461 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SLIT tablets of HDM allergen extracts, 3 different doses (C)
Description: Two sublingual tablets daily for 13 months
Study NCT01930461 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching the SLIT tablets of HDM allergen extracts
Description: Two sublingual tablets daily for 13 months
Study NCT01540032 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low salicylate diet
Description: Patients will avoid foods from the 'high salicylate' group completely. They can eat foods from the 'low salicylate' group freely and just eat foods from the medium group occasionally, and not in large amounts.
Study NCT01540032 — intervention group
Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: Normal diet
Description: Patients will eat their usual diet.
Study NCT04582721 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Implantable Neurostimulator System (Spectra WaveWriter™ Spinal Cord Stimulator System), (Boston Scientific Neuromodulation Corporation, Valencia, California (CA), USA)
Description: the participants with chronic intractable back or back and leg pain will be implanted with the stimulation lead(s). The leads are initially connected to an external trial neurostimulator. Patients will be implanted with two epidural leads and two subcutaneous leads. A three weeks trial phase will follow. The first two days after the leads implant will be without stimulation and thereafter alternating stimulation every week will start, randomly ordering the treatments using a Williams design balanced for first-order carryover effects (i.e. incorporating 6 different treatment orders), from:~* 1) CON-SCS with Subcutaneous stimulation~* 2) HF-SCS~* 3) Combination Therapy A patient's favored SCS mode, providing that there is at least 50% reduction in pain intensity on the NRS in the trial phase, will then be implanted and patients will be followed up for 12 months.
Study NCT04627376 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multimodal education and support program for cancer related cachexia prevention
Description: 12-weeks multimodal program includes: 4 meetings (with cancer nurse and clinical dietician). In this 4 meetings (about 30 minutes) they will have blood tests (CRP, Albumin levels), body composition measurements, questionnaires, education on their diet and symptom management related to anti cancer treatment.
Study NCT01701284 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS)
Study NCT03937466 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cooling mattress pad
Description: The cooling mattress pad is a commercially available pad designed to be placed between the top of a mattress and bed sheets. It allows for precise temperature regulation in one's bed.
Study NCT02236533 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: whole grain pasta
Description: Volunteers were fed with probiotic fortified pasta or control pasta once a day for 12 weeks.
Study NCT02236533 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: whole grain pasta
Description: Volunteers were fed with probiotic fortified pasta or control pasta once a day for 12 weeks.
Study NCT02224456 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate
Description: White, almond-shaped, film-coated tablet containing 300 mg of TDF, debossed with GILEAD and 4331 on one side of the tablet.
Study NCT04409665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Patient will be sedated using Ketamine 2 minutes before the LISA procedure. 10 minutes prior the procedure and during the procedure the patient's pain and/or discomfort will be evaluated using COMFORT and FANS scales
Study NCT04409665 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucose
Description: Patient will be sedated using Glucose 2 minutes before the LISA procedure. 10 minutes prior the procedure and during the procedure the patient's pain and/or discomfort will be evaluated using COMFORT and FANS scales
Study NCT03389386 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood withdrawal for laboratory analysis
Description: Participants in this study will have their peripheral blood sampled from the cubital vein and the total volume withdrawn for the purposes of this study will be no more than 22 mL per person.~Parameters of interest in the laboratory analysis will include serum catestatin levels, NT-proBNP levels, hs-cTnI, parameters of inflammation and renal function as well as standard biochemistry and complete blood count (CBC) panels.
Study NCT03389386 — intervention group
Intervention type: OTHER
Intervention: Standard-of-care treatment
Description: Patients diagnosed with chronic heart failure will receive optimal standards of care in terms of pharmacologic management, according to their current clinical condition.
Study NCT03389386 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Transthoracic echocardiography (TTE)
Description: Participants from both groups will undergo transthoracic echocardiography examination that will measure established hemodynamic parameters of systolic and diastolic cardiac function as well as parameters of LV and RV strain in the selected subset of patients.
Study NCT04574583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SX-682
Description: SX-682 will be given orally at designated dose twice a day every day
Study NCT04574583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M7824
Description: Subjects will receive M7824 at a flat dose of 1,200 mg intravenously on Days 1 and 15 of each cycle.
Study NCT04574583 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-BN-CV301
Description: MVA-BN-CV301 will be given as four subcutaneous injections (4x10\^8 Inf.U/0.5ml twice during Cycle 1 (Days 1 and 15)
Study NCT04574583 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant fowlpox viral (FPV)-CV301
Description: FPV-CV301 will be given as one subcutaneous injection (1x10\^9 Inf.U/0.5ml) on Day 1 starting at cycle 2 through cycle 5 (every 4 weeks) then on Day 1 of every 3 cycles (Cycles 8 and Cycle 11).
Study NCT03526965 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga Chikitsa
Description: Intervention consisted of combination of static movements, yoga style exercise, yoga postures, breathing practices, relaxation and yoga counselling.
Study NCT03526965 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Intervention included pain medications and exercise movements for neck.
Study NCT03526965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Intervention included pain medications and exercise movements for neck.
Study NCT02201251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate
Description: Topiramate weight based dosing for participants 2 to \<10 years of age not to exceed 350 mg/day, as tolerated; not to exceed 400 mg/day in participants 10-15 years of age, as tolerated.
Study NCT02201251 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levetiracetam
Description: Levetiracetam weight based dosing for all participants 2-15 years of age, not to exceed 60 mg/kg/day, as tolerated. The maximum recommended daily dosage is 3,000 mg.
Study NCT01197963 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Sleeve Gastrectomy and Ileal transposition
Description: Laparoscopic sleeve gastrectomy with ileal transposition
Study NCT01197963 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: dietary and medical management
Description: dietary and medical routine management patients are currently following with an endocrinologist.
Study NCT03301909 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PillCam™ Endoscopy System
Description: Subject may be assigned to any procedure involving modification of any of the PillCam™ Endoscopy System component as listed in the arm description.
Study NCT03301909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bowel prep combination
Description: Subject may be assigned to any bowel preparation combination.
Study NCT03630666 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IADT
Description: Patient will receive one injection of IADT at randomization
Study NCT03630666 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: IADT + radiotherapy
Description: Patient will receive one injection of IADT at randomization then will receive irradiation 3 months after injection of IADT
Study NCT03202758 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Durvalumab, Tremelimumab and ,FOLFOX
Description: Study will be performed in 2 step:~STEP 1 (phase Ib) will assess the safety of the combination of Durvalumab 750mg q2w + tremelimumab 75mg q4w + FOLFOX during the 2 first cycles of treatment (1 month)~STEP 2 (phase II) will assess the efficacy of the combination of Durvalumab 750mg q2w + tremelimumab 75mg q4w + FOLFOX
Study NCT04094870 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sertraline
Description: daily SSRI (Sertraline 25mg)
Study NCT04094870 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Interpersonal therapy
Description: 11 sessions over a 24-week period
Study NCT01769209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Administered subcutaneously (SC) at 1.3 mg/m², on Days 1, 4, 8, and 11.
Study NCT01769209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin hydrochloride (HCl)
Description: Administered intravenously (IV) over 15 min at 60mg/m², on Day 1.
Study NCT01769209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-Asparaginase
Description: Administered intravenously (IV) or intramuscularly (IM) 2500 U/m² (maximum 3750 U), on Days 5 and 22.
Study NCT01769209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine sulfate
Description: Administered by intravenous (IV) push at 1.5 mg/m² (maximum 2 mg), on Days 1, 8, 15, and 22.
Study NCT01769209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Administered orally (PO) at 10 mg/m², daily on Days 1 to 14.
Study NCT01769209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Administered intrathecally (IT) at 100 mg, on Day 1
Study NCT01769209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Administered intrathecally (IT) at 15 mg, on Day 15.
Study NCT01220349 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Echocardiographic 2D strain analysis
Description: Conventional transthoracic echocardiography with acquisitions for strain analysis by speckle tracking (2D strain)
Study NCT01489722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1208
Description: Daily oral doses of AZD1208 for 28 day cycles until progression or unacceptable toxicity develops. Starting dose will be 120 mg and will be escalated in successive cohorts until an MTD is established.
Study NCT02637193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Description: Multiple doses of Venlafaxine for 14 days plus 3 days of down titration
Study NCT02637193 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: 400 mg single dose moxifloxacin
Study NCT02637193 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Drug - placebo
Description: Placebo administered for 16 days
Study NCT02322047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prazosin
Description: Prazosin Dosing Days 1-2: 1 mg @ 9PM Days 3-4: 1 mg @ 9AM, 3PM, 9PM Days 5-7: 2 mg @ 9AM, 3PM, 9PM Days 8-10: 2mg @ 9 AM, 3 PM; 8mg @ 9 PM Days 11-14: 4mg @ 9 AM, 3 PM; 8mg @ 9 PM Days 15-42: 4mg @ 9 AM, 3 PM; 8mg @ 9 PM
Study NCT02322047 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prazosin
Description: Prazosin Dosing Days 1-2: 1 mg @ 9PM Days 3-4: 1 mg @ 9AM, 3PM, 9PM Days 5-7: 2 mg @ 9AM, 3PM, 9PM Days 8-10: 2mg @ 9 AM, 3 PM; 8mg @ 9 PM Days 11-14: 4mg @ 9 AM, 3 PM; 8mg @ 9 PM Days 15-42: 4mg @ 9 AM, 3 PM; 8mg @ 9 PM
Study NCT02322047 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone
Description: Naltrexone Dosing Days 1-42: 50mg @ 9PM
Study NCT02322047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: Naltrexone Dosing Days 1-42: 50mg @ 9PM
Study NCT02322047 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (Prazosin)
Description: Placebo Dosing Days 1-2: 1 mg @ 9PM Days 3-4: 1 mg @ 9AM, 3PM, 9PM Days 5-7: 2 mg @ 9AM, 3PM, 9PM Days 8-10: 2mg @ 9 AM, 3 PM; 8mg @ 9 PM Days 11-14: 4mg @ 9 AM, 3 PM; 8mg @ 9 PM Days 15-42: 4mg @ 9 AM, 3 PM; 8mg @ 9 PM
Study NCT02322047 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Prazosin)
Description: Placebo Dosing Days 1-2: 1 mg @ 9PM Days 3-4: 1 mg @ 9AM, 3PM, 9PM Days 5-7: 2 mg @ 9AM, 3PM, 9PM Days 8-10: 2mg @ 9 AM, 3 PM; 8mg @ 9 PM Days 11-14: 4mg @ 9 AM, 3 PM; 8mg @ 9 PM Days 15-42: 4mg @ 9 AM, 3 PM; 8mg @ 9 PM
Study NCT02322047 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Naltrexone)
Description: Placebo Dosing Days 1-42: 50mg @ 9PM
Study NCT02322047 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (Naltrexone)
Description: Placebo Dosing Days 1-42: 50mg @ 9PM
Study NCT01572766 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FRAX Assessment Tool
Description: FRAX Assessment Tool is designed to assess risk for fracture based on country of origin, race, and other factors.
Study NCT01876862 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Antiretroviral treatment interruption
Description: pilot study in chronically HIV-infected patients with an ultralow HIV reservoir undergoing treatment-interruption.
Study NCT02282319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: spinal dexmedetomidine 0.5 mcg
Description: Administration of dexmedetomidine 0.5 mcg
Study NCT02282319 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: spinal chloroprocaine 40 mg
Description: spinal anesthesia with chloroprocaine 40 mg
Study NCT02282319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV dexmedetomidine 0.5 mcg/kg
Description: intravenous administration of dexmedetomidine 0.5 mcg/kg
Study NCT02551744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: histamine-2 receptor antagonist group
Description: famotidine tab 40 mg qd for 6 months.
Study NCT02551744 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: proton pump inhibitor group
Description: pantoprazole tab 40 mg qd for 6 months.
Study NCT02058420 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low tocotrienols group
Description: 300 mg tocotrienols daily
Study NCT02058420 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High tocotrienols group
Description: 600 mg tocotrienols daily
Study NCT02479035 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Red raspberry meal 1
Description: \~125 g fresh weight (1 cup equivalent)
Study NCT02479035 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Red raspberry meal 2
Description: \~250 g fresh weight (2 cup equivalent)
Study NCT02479035 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control meal
Description: 0 g red raspberry
Study NCT04132570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: Participants will self-administer 2 nasal sprays of Budesonide (64 mcg/spray) once daily up to 10 +\\- 3 Days.
Study NCT04132570 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will self-administer 2 nasal sprays of matching placebo once daily up to 10 +\\- 3 Days.